Israel-based surgical glue developer LifeBond closed its series D round at $27m yesterday after raising additional capital from pharmaceutical company investors including pharmaceutical company Sino Biopharmaceutical.
The round also included healthcare company Johnson & Johnson, Giza Venture Capital, Aurum Ventures, Pitango Venture Capital, GlenRock Israel and Zitelman Group and Adams Street Partners.
Johnson & Johnson had already joined undisclosed investors in November 2014 to provide LifeBond with $12.5m of a planned $25m series D.
LifeBond’s flagship product, LifeSeal Surgical…
